The Merger was consummated on June 10, 2026, resulting in Merger Sub merging with the Issuer and the Issuer becoming a wholly owned subsidiary of Parent. Each share of Common Stock was converted into the right to receive $180.00 in cash per share, and the Reporting Persons' 4,590,873 shares were converted into this right, along with 1,119 restricted share units held by Mr. Koffey. As a result, the Reporting Persons no longer beneficially own any shares of Common Stock.

Agreements · The information regarding the Merger and the conversion of shares into cash consideration, as detailed in Item 4, is incorporated by reference.

Agreements · Redmile Funds, excluding RBI II, acquired Pre-Funded Warrants in an underwritten offering at $3.9999 per warrant, allowing them to purchase up to 1,000,000 shares of Common Stock at an exercise price of $0.0001 per warrant, subject to a Beneficial Ownership Blocker.

On June 6, 2026, the Issuer, Treeline Biosciences, Inc., and Siri Merger Sub, Inc. entered into a Merger Agreement. The Casdin Parties also entered into a Voting Agreement, agreeing to vote their securities in favor of the merger, the issuance of shares to Company stockholders, a name change for the Issuer to "Treeline Biosciences Holdings, Inc.", a reverse stock split, and the adoption of post-closing equity incentive plans, and against any actions that would prevent or delay the merger.

Agreements · On January 23, 2022, Casdin PMF and Casdin PGEII entered into a Stock Purchase Agreement with the Issuer to purchase 78,750 and 33,750 shares of Series B-1 Preferred Stock for $78,750,000 and $33,750,000, respectively. Concurrently, Casdin PMF and Casdin PGEII provided term loans of $8,750,000 and $3,750,000, respectively, which were subsequently converted into 10,696 and 4,584 shares of Series B-1 Preferred Stock upon the issuance of the preferred stock.

Agreements · In connection with Jade Biosciences, Inc.'s public offering, the Reporting Persons entered into a lock-up agreement for 60 days, restricting the sale of company securities without underwriter consent. The Reporting Persons did not participate in the offering.

Between February 13, 2026, and May 22, 2026, Juniper Targeted Opportunity Fund, L.P. purchased 657,926 shares of Orthofix Medical Inc. in the open market for approximately $7,413,751.

Agreements · There are no contracts, arrangements, understandings or relationships between any of the Reporting Persons or between any of the Reporting Persons and any other person with respect to any securities of Orthofix Medical Inc., except as described in this Schedule 13D.

Baker Brothers Advisors, on behalf of its funds, entered into a Deed of Waiver with Kiniksa Pharmaceuticals International, plc, irrevocably waiving their right to convert Class A1 and Class B1 ordinary shares into Class A or Class B ordinary shares if such conversion would result in the funds beneficially owning more than 49.9% of the outstanding voting rights in the Issuer. The funds hold securities for investment purposes and may adjust their holdings based on various market and business factors.

Agreements · Baker Brothers Advisors, on behalf of its funds, entered into a Deed of Waiver with Kiniksa Pharmaceuticals International, plc, waiving the funds' right to convert Class A1 and Class B1 ordinary shares if it would lead to them owning more than 49.9% of the Issuer's voting rights. The Issuer agreed not to effect conversions circumventing this waiver, and the funds agreed not to transfer these shares to affiliates unless the transferee adheres to similar restrictions.